Info

Canji, Inc. is a biotechnology company engaged in the development of innovative therapeutics based on tumor suppressor genes, cell-cycle regulators and growth modulators. The company,s initial research efforts are focused on the two best-characterized tumor suppressor genes, p53 and RB, and on identifying efficient, reproducible gene delivery systems. Canji is a wholly owned subsidiary of Schering-Plough Corporation (NYSE: SGP) of Kenilworth, N.J., a research-based company engaged in the discovery, development, manufacturing and marketing of pharmaceutical products worldwide.